Rong Tang
SVP
Ms. Tang has more than 30 years of experience in finance and investment management. She is a versatile and senior investor with expertise spanning the primary market, public funds, commercial banks, and industrial mergers & acquisitions. She excels in deeply integrating industrial thinking, capital operation, and government resources, with a focus on the healthcare sector, where she pursues long-term value investment and industrial ecosystem empowerment. Ms. Tang has served as a partner at Sanze Ventures and Yicun Capital. She has also held management positions at several renowned financial institutions, including Harfor Fund, Franklin Templton Sealand Fund, and Agricultural Bank of China. Currently, she acts as an independent director of Holitech Technology Co., Ltd (002217.SZ). Ms. Tang holds a Bachelor's Degree in Literature from Central South University and a Master's Degree in Economics from Huazhong University of Science and Technology.
Jun Shao, Ph.D.
U.S. GM & COO
Jun Shao is responsible for overseeing the company's operations in the US, regulatory submissions and registrations, GMP and GCP quality assurance systems, clinical drug supply and logistics, later-stage product pipeline development. Prior to joining the company, Dr. Shao held R&D and Management positions in several US and Chinese leading pharmaceutical companies, including Abbott laboratories, Procter and Gamble Pharmaceuticals, eVenus Pharmaceutical Laboratories (Jiangsu Hengrui’s US subsidiary), and Zhejiang Hisun Pharmaceutical. With over 30 years of academic and industry experiences in China and the US, Dr. Shao has a strong background in drug research and development, manufacturing, regulatory affairs, and quality assurance. He has successfully filed over a dozen of IND/ANDA submissions with the US FDA and led passing numerous regulatory GMP inspections by Chinese NMPA, US FDA, EMA, WHO and Health Canada.
Robert Huang，PhD & MBA
Founder，Chair and CEO
A serial entrepreneur with over 30 years of experience in the pharmaceutical and biotech industries, Dr. Robert Huang has held roles with increasing responsibilities, including post-doctoral fellow, group head, director of business development, senior director of strategy and corporate development, and president at Abbott Labs, Millipore, Tularik, Applied Biosystems, and Abgent, respectively. He is the founder of iBioSource in San Francisco and Suzhou in 2011, and Coherent Biopharma in 2016. Dr. Huang earned his PhD in Biochemistry at The Ohio State University, an MBA at the Johnson Graduate School of Management at Cornell University, and a BS/MS in Chemistry at Peking University. He has authored 18 papers, including 2 in Nature and 2 in Nature Structural Biology, and holds 15 patents worldwide.